BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 32729618)

  • 21. Analysis of DNA Damage Response Gene Alterations and Tumor Mutational Burden Across 17,486 Tubular Gastrointestinal Carcinomas: Implications for Therapy.
    Parikh AR; He Y; Hong TS; Corcoran RB; Clark JW; Ryan DP; Zou L; Ting DT; Catenacci DV; Chao J; Fakih M; Klempner SJ; Ross JS; Frampton GM; Miller VA; Ali SM; Schrock AB
    Oncologist; 2019 Oct; 24(10):1340-1347. PubMed ID: 31040255
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pathology of BRCA1- and BRCA2-associated Breast Cancers: Known and Less Known Connections.
    Fountzilas E; Konstantopoulou I; Vagena A; Apostolou P; Papadimitriou C; Christodoulou C; Tryfonopoulos D; Manousou K; Delimitsou A; Papamentzelopoulou M; Fountzilas G; Yannoukakos D; Fostira F
    Clin Breast Cancer; 2020 Apr; 20(2):152-159. PubMed ID: 31980407
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Associations between RAD51D germline mutations and breast cancer risk and survival in BRCA1/2-negative breast cancers.
    Chen X; Li Y; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xie Y
    Ann Oncol; 2018 Oct; 29(10):2046-2051. PubMed ID: 30165555
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tumor Mutation Burden and Prognosis in Patients with Colorectal Cancer Treated with Adjuvant Fluoropyrimidine and Oxaliplatin.
    Lee DW; Han SW; Bae JM; Jang H; Han H; Kim H; Bang D; Jeong SY; Park KJ; Kang GH; Kim TY
    Clin Cancer Res; 2019 Oct; 25(20):6141-6147. PubMed ID: 31285374
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Germline Mutations in Cancer Susceptibility Genes in a Large Series of Unselected Breast Cancer Patients.
    Sun J; Meng H; Yao L; Lv M; Bai J; Zhang J; Wang L; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xie Y
    Clin Cancer Res; 2017 Oct; 23(20):6113-6119. PubMed ID: 28724667
    [No Abstract]   [Full Text] [Related]  

  • 26. Prevalence of BRCA1/BRCA2 mutations in a Brazilian population sample at-risk for hereditary breast cancer and characterization of its genetic ancestry.
    Fernandes GC; Michelli RA; Galvão HC; Paula AE; Pereira R; Andrade CE; Felicio PS; Souza CP; Mendes DR; Volc S; Berardinelli GN; Grasel RS; Sabato CS; Viana DV; Mauad EC; Scapulatempo-Neto C; Arun B; Reis RM; Palmero EI
    Oncotarget; 2016 Dec; 7(49):80465-80481. PubMed ID: 27741520
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification of a novel BRCA2 and CHEK2 A-C-G-C haplotype in Turkish patients affected with breast cancer.
    Haytural H; Yalcinkaya N; Akan G; Arikan S; Ozkok E; Cakmakoglu B; Yaylim I; Aydin M; Atalar F
    Asian Pac J Cancer Prev; 2013; 14(5):3229-35. PubMed ID: 23803109
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Toward the precision breast cancer survival prediction utilizing combined whole genome-wide expression and somatic mutation analysis.
    Zhang Y; Yang W; Li D; Yang JY; Guan R; Yang MQ
    BMC Med Genomics; 2018 Nov; 11(Suppl 5):104. PubMed ID: 30454048
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeted next-generation sequencing identifies clinically relevant somatic mutations in a large cohort of inflammatory breast cancer.
    Liang X; Vacher S; Boulai A; Bernard V; Baulande S; Bohec M; Bièche I; Lerebours F; Callens C
    Breast Cancer Res; 2018 Aug; 20(1):88. PubMed ID: 30086764
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations.
    Rennert G; Bisland-Naggan S; Barnett-Griness O; Bar-Joseph N; Zhang S; Rennert HS; Narod SA
    N Engl J Med; 2007 Jul; 357(2):115-23. PubMed ID: 17625123
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Germline mutation in DNA-repair genes is associated with poor survival in BRCA1/2-negative breast cancer patients.
    Fan Z; Hu L; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xu Y; Xie Y
    Cancer Sci; 2019 Oct; 110(10):3368-3374. PubMed ID: 31432574
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification of gene expression profiles and immune cell infiltration signatures between low and high tumor mutation burden groups in bladder cancer.
    Wu Z; Wang M; Liu Q; Liu Y; Zhu K; Chen L; Guo H; Li Y; Shi B
    Int J Med Sci; 2020; 17(1):89-96. PubMed ID: 31929742
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Twenty-one-gene recurrence score assay in BRCA-associated versus sporadic breast cancers: Differences based on germline mutation status.
    Shah PD; Patil S; Dickler MN; Offit K; Hudis CA; Robson ME
    Cancer; 2016 Apr; 122(8):1178-84. PubMed ID: 26859126
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A novel tumor mutational burden estimation model as a predictive and prognostic biomarker in NSCLC patients.
    Tian Y; Xu J; Chu Q; Duan J; Zhang J; Bai H; Yang Z; Fang W; Cai L; Wan R; Fei K; He J; Gao S; Zhang L; Wang Z; Wang J
    BMC Med; 2020 Aug; 18(1):232. PubMed ID: 32843031
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tumor mutation burden, immune checkpoint crosstalk and radiosensitivity in single-cell RNA sequencing data of breast cancer.
    Jang BS; Han W; Kim IA
    Radiother Oncol; 2020 Jan; 142():202-209. PubMed ID: 31767471
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Integration of somatic mutation, expression and functional data reveals potential driver genes predictive of breast cancer survival.
    Suo C; Hrydziuszko O; Lee D; Pramana S; Saputra D; Joshi H; Calza S; Pawitan Y
    Bioinformatics; 2015 Aug; 31(16):2607-13. PubMed ID: 25810432
    [TBL] [Abstract][Full Text] [Related]  

  • 37.
    Tang Y; Li J; Xie N; Yang X; Liu L; Wu H; Tian C; He Y; Wang X; He Q; Hu ZY; Ouyang Q
    Aging (Albany NY); 2020 Jan; 12(2):1577-1590. PubMed ID: 31980592
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identification of prognostic significance of BIRC5 in breast cancer using integrative bioinformatics analysis.
    Dai JB; Zhu B; Lin WJ; Gao HY; Dai H; Zheng L; Shi WH; Chen WX
    Biosci Rep; 2020 Feb; 40(2):. PubMed ID: 32043523
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Association of Somatic Mutations of ADAMTS Genes With Chemotherapy Sensitivity and Survival in High-Grade Serous Ovarian Carcinoma.
    Liu Y; Yasukawa M; Chen K; Hu L; Broaddus RR; Ding L; Mardis ER; Spellman P; Levine DA; Mills GB; Shmulevich I; Sood AK; Zhang W
    JAMA Oncol; 2015 Jul; 1(4):486-94. PubMed ID: 26181259
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The transcription factor CBFB mutations indicate an improved survival in HR+/HER2- breast cancer.
    Guo L; Chen B; Zhang G; Wang Y; Cao L; Ren C; Wen L; Lin J; Wei G; Liao N
    Gene; 2020 Oct; 759():144970. PubMed ID: 32711101
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.